RxDoctor Payments Data

Luis Egelsee, MD

Family Medicine · Leander, TXNPI 1407969140

Payments from drug & device makers

$7,867in general payments, 2019–2025

Across 374 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$891
  • Novo Nordisk$824
  • Lilly USA, LLC$391
  • Boehringer Ingelheim$390
  • Amgen$348
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,855100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,867 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$163,383
Medicare patients
383
Services billed
2,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$67,675
MounjaroTirzepatide44$66,180
JardianceEmpagliflozin38$51,785
EliquisApixaban46$45,495
FarxigaDapagliflozin Propanediol33$40,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$33,720
JanuviaSitagliptin Phosphate24$29,060
Breo ElliptaFluticasone/Vilanterol17$9,121
SymbicortBudesonide/Formoterol Fumarate25$8,604
JanumetSitagliptin Phos/Metformin Hcl12$7,574
Levothyroxine Sodium493$7,032
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,702
Atorvastatin Calcium542$4,137
Rosuvastatin Calcium230$3,094
Gabapentin171$2,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$824$67,67558 claims
Lilly USA, LLCMounjaro$391$66,18044 claims
Boehringer IngelheimJardiance$390$51,78538 claims
AstraZenecaFarxiga, Symbicort$1,714$49,08758 claims
PfizerEliquis$346$45,49546 claims
GSKTrelegy Ellipta, Breo Ellipta$261$42,84139 claims
MerckJanuvia, Janumet$30$36,63336 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$7,032493 claims
AbbVieSynthroid$891$2,35033 claims
Sanofi-aventis U.S. LLCLantus$14$1,35221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Leander

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →